Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | RXRG | P48443 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607526 | 0.85 | MAOB (0.48) | LMNAMAPK1SMN1; SMN2KDM4EMAOB | |
| SCHEMBL366495 | 0.82 | HTT (0.57) | WDR5KMT2AKCNH2LMNAMAPK1 | |
| SCHEMBL6273430 | 0.82 | DRD2 (0.62) | WDR5KMT2AKCNH2LMNAMAPK1 | |
| SCHEMBL24854715 | 0.81 | KMT2A (0.51) | WDR5KMT2AKCNH2LMNAMAPK1 | |
| SCHEMBL28539724 | 0.80 | CYP1A1 (0.43) | MAOBRXRARXRB | |
| SCHEMBL30114007 | 0.79 | MAOB (0.58) | LMNAMAPK1KDM4EMAOB | |
| SCHEMBL315808 | 0.79 | TP53 (0.59) | WDR5KMT2AKCNH2LMNAMAPK1 | |
| SCHEMBL2047854 | 0.79 | MAOB (0.58) | LMNAMAPK1KDM4EMAOB | |
| SCHEMBL30167806 | 0.79 | TP53 (0.59) | WDR5KMT2AKCNH2LMNAMAPK1 | |
| SCHEMBL9808215 | 0.79 | LMNA (0.67) | WDR5KMT2AKCNH2LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107580599-A | HERBICIDAL COMPOUNDS | 先正达参股股份有限公司 | 2018-01-12 | — | — | CN | disclosed |
| CN-107567455-A | Herbicidal compounds | 先正达参股股份有限公司 | 2018-01-09 | — | — | CN | disclosed |
| CN-105008375-B | Tetrahydroimidazo [1,5-d ] [1,4] oxazepine derivatives | 卫材R&D管理有限公司 | 2016-12-28 | — | — | CN | disclosed |
| US-9168248-B2 | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase | MERCK CANADA INC. (CA) | 2015-10-27 | — | — | US | disclosed |
| EP-2398809-B1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC (CA) | 2015-07-08 | — | — | EP | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8383643-B2 | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase | MERCK CANADA INC. (CA) | 2013-02-26 | — | — | US | disclosed |
| EP-2459568-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Limited (CA) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122912-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2421835-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| EP-2398809-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Canada Inc. (CA) | 2011-12-28 | — | — | EP | disclosed |
| US-20110312952-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. | 2011-12-22 | — | — | US | disclosed |
| WO-2011047481-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011011872-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2011-02-03 | — | — | WO | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| WO-2010094120-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312952-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | WDR5 3359/4885KMT2A 4207/4885KCNH2 4330/4885 |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | ORAI1, TRPV1, CACNA1E | WDR5 2894/4885KMT2A 3401/4885KCNH2 41/4885 |
| US-20120122912-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | WDR5 3359/4885KMT2A 4207/4885KCNH2 4330/4885 |
| US-20100273744-A1 | COMPOUNDS | LTC4S, HRH4, HRH2 | WDR5 4341/4885KMT2A 1734/4885KCNH2 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.